GT Biopharma, Inc. (GTBP) - Latest Market Data

Price & Market Data

Price: $0.453

Daily Change: +$0.0198 / 4.37%

Daily Range: $0.427 - $0.489

Market Cap: $15,867,678

Daily Volume: 2,556,641

Performance Metrics

1 Week: 0.93%

1 Month: 25.69%

3 Months: -3.19%

6 Months: -36.63%

1 Year: -84.31%

YTD: -43.13%

About GT Biopharma, Inc. (GTBP)

Discover the market dynamics of GT Biopharma, Inc. (GTBP). The stock stands at 0.453, with its daily performance showing a change of +$0.0198 / 4.37%. Its market cap is valued at 15,867,678. Explore its 6-month (-36.63%) and 1-week (0.93%) performance for a quick overview.

Company Details

Employees: 1

Sector: Health technology

Industry: Pharmaceuticals: major

Country: United States

Details

GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, that is in phase 1 dose escalation basket trial that targets B7-H3 on the surface of advanced solid tumors;and GTB-7550, a pre-clinical stage product candidate in development for the treatment of lupus and other autoimmune disorders. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in San Francisco, California.

Selected stocks

DAX Germany ETF (DAX)

Deswell Industries, Inc. (DSWL)

Nano Labs Ltd (NA)

Zenta Group Company Limited (ZTG)

Commerce.com, Inc. - Series 1 (CMRC)